細(xì)胞轉(zhuǎn)染試劑已經(jīng)成為研究和控制真核細(xì)胞基因功能的常規(guī)試劑，轉(zhuǎn)染試劑在基因功能研究、基因表達(dá)調(diào)控、突變分析，以及基因治療、細(xì)胞治療、蛋白生產(chǎn)、疫苗生產(chǎn)等方面應(yīng)用廣泛。

針對(duì)DNA轉(zhuǎn)染試劑與RNA轉(zhuǎn)染試劑，翌圣均擁有雄厚的研發(fā)與生產(chǎn)團(tuán)隊(duì)，不斷優(yōu)化配方，改良生產(chǎn)工藝，推出了多款以陽離子脂質(zhì)體與陽離子聚合物為基礎(chǔ)的產(chǎn)品，為廣大科研院校與企業(yè)提供的產(chǎn)品，產(chǎn)品線覆蓋轉(zhuǎn)染試劑涉及的各個(gè)領(lǐng)域。

轉(zhuǎn)染試劑的選擇，需要根據(jù)實(shí)驗(yàn)?zāi)康呐c實(shí)驗(yàn)內(nèi)容，如轉(zhuǎn)染的物質(zhì)、具體的細(xì)胞、操作的便捷性等因素綜合考量，小編進(jìn)行了以下的區(qū)分，供大家參考。

1、DNA/質(zhì)粒轉(zhuǎn)染試劑

A、10 kb以下DNA/質(zhì)粒

Hieff Trans™ Liposomal Transfection Reagent 脂質(zhì)體核酸轉(zhuǎn)染試劑

產(chǎn)品簡(jiǎn)介

Hieff Trans™脂質(zhì)體核酸轉(zhuǎn)染試劑是一種多用途的脂質(zhì)體轉(zhuǎn)染試劑，適用于DNA、RNA和寡核苷酸的轉(zhuǎn)染，對(duì)大多數(shù)真核細(xì)胞具有很高的轉(zhuǎn)染效率。其*的配方使其可直接加入培養(yǎng)基中，血清的存在不會(huì)影響轉(zhuǎn)染效率，這樣可以減少去除血清對(duì)細(xì)胞的損傷。轉(zhuǎn)染后不需要除去核酸-Hieff Trans™復(fù)合物或更換新鮮培養(yǎng)基，也可在4～6小時(shí)后除去。

圖. Hieff Trans™轉(zhuǎn)染試劑操作流程示意圖

Hieff Trans™以無菌的液體形式提供。通常情況下對(duì)于24孔板轉(zhuǎn)染，每次用1.5 μL左右，則1 mL Hieff Trans™約可做660次轉(zhuǎn)染；對(duì)于6孔板，每次用6 μL左右，則1 mL Hieff Trans™約可做160次轉(zhuǎn)染；

B、10 kb以上DNA/質(zhì)粒

Polyethylenimine Linear (PEI) MW40000（rapid lysis） 線性PEI轉(zhuǎn)染試劑（速溶型）MW40000

PEI 40000是一種分子量為40000的高電荷陽離子聚合物，非常容易結(jié)合帶負(fù)電荷的核酸分子，形成復(fù)合物，并使該復(fù)合物進(jìn)入細(xì)胞中。PEI 40000是一種瞬時(shí)轉(zhuǎn)染試劑，細(xì)胞毒性低，轉(zhuǎn)染效率高，在HEK293和CHO等細(xì)胞中基因表達(dá)效率較高。目前已經(jīng)驗(yàn)證線性PEI轉(zhuǎn)染試劑廣泛適用于多種細(xì)胞系包括HEK-293、HEK293T、CHO-K1、COS-1、COS-7、NIH/3T3 、Sf9、HepG2和Hela細(xì)胞等。轉(zhuǎn)染效率高達(dá)80%~90%。

2、RNA轉(zhuǎn)染試劑

Hieff Trans™ siRNA/miRNA體外轉(zhuǎn)染試劑

Hieff Trans™siRNA/miRNA體外轉(zhuǎn)染試劑是一種非脂質(zhì)體PEI陽離子、兩性分子轉(zhuǎn)染試劑，為siRNA轉(zhuǎn)染到哺乳動(dòng)物細(xì)胞中而開發(fā)。適用于siRNA和miRNA的轉(zhuǎn)染。

該產(chǎn)品可在廣泛的細(xì)胞系中，實(shí)現(xiàn)1 nM的siRNA超過90%的表達(dá)效率，避免了脫靶效應(yīng)。適用于多種細(xì)胞轉(zhuǎn)染，包括Hela、MCF-7、HepG2、CHO等貼壁細(xì)胞；以及難以轉(zhuǎn)染的懸浮細(xì)胞系，如K562或THP-1細(xì)胞，可達(dá)到80%的沉默效率；同時(shí)還包括一些原代細(xì)胞，原代人成纖維細(xì)胞和原代人肝細(xì)胞等，可達(dá)到80%的沉默效率。

3、DNA/RNA共轉(zhuǎn)染試劑

4、工業(yè)生產(chǎn)轉(zhuǎn)染試劑系列產(chǎn)品

已驗(yàn)證細(xì)胞系列表

1、脂質(zhì)體與PEI轉(zhuǎn)染試劑的差異，可查看1分鐘解鎖兩代轉(zhuǎn)染試劑的差異
2、轉(zhuǎn)染試劑常見問題，可查看轉(zhuǎn)染效率低？小翌手把手教你做轉(zhuǎn)染實(shí)驗(yàn)與太實(shí)用了！轉(zhuǎn)染試劑常見問題大全，你想要的答案這里都有

3、Hieff Trans™ Liposomal Transfection Reagent 脂質(zhì)體核酸轉(zhuǎn)染試劑不同細(xì)胞轉(zhuǎn)染中DNA與試劑用量參考，可查看40802參考數(shù)據(jù)

4、線性PEI轉(zhuǎn)染試劑MW40000（速溶型）進(jìn)一步介紹，可查看轉(zhuǎn)染新寵——PEI MAX （線性PEI MW 40000）更高效的轉(zhuǎn)染試劑

5、大牛們的高分文章選讀，可查看IF55分！翌圣轉(zhuǎn)染試劑助力高分文章、翌圣明星CP--轉(zhuǎn)染試劑與PCR產(chǎn)品又登《Cell》期刊與超燃！翌圣轉(zhuǎn)染試劑助力這個(gè)團(tuán)隊(duì)連發(fā)3篇IF10+文章

[1] Liu R, Yang J, et al. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins. Nat Biotechnol. 2022 Jan 3. (IF:55)華東理工大學(xué)生物工程學(xué)院楊弋團(tuán)隊(duì)

[2] Luo J, Yang Q, et al. TFPI is a colonic crypt receptor for TcdB from hypervirulent clade 2 C. difficile. Cell. 2022 Mar 17.（41.582）西湖大學(xué)陶亮團(tuán)隊(duì)

[3] Zhou J, Chen P, et al. Cas12a variants designed for lower genome-wide off-target effect through stringent PAM recognition. Mol Ther. 2022 Jan 5.(IF:11.454)武漢大學(xué)生命科學(xué)學(xué)院殷雷團(tuán)隊(duì)

[4] Chen S, Cao X, et al. circVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c-Myc Translation. Adv Sci (Weinh). 2022 Jan 24.(IF:16.808)中國(guó)科學(xué)院北京生命科學(xué)研究院趙方慶團(tuán)隊(duì)

[5] Gu C, Wang Y, et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022 Jan 6.(11.161)南京中醫(yī)藥大學(xué)楊燁顧春艷團(tuán)隊(duì)

[6] Zhang Y, Yu X, et al. Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication. Clin Transl Med. 2022 Feb.(11.492)南京中醫(yī)藥大學(xué)楊燁顧春艷團(tuán)隊(duì)

[7] Qin J, Cai Y, et al. Molecular mechanism of agonism and inverse agonism in ghrelin receptor. Nat Commun. 2022 Jan 13.(14.9)四川大學(xué)生物治療國(guó)家重點(diǎn)實(shí)驗(yàn)室邵振華團(tuán)隊(duì)

[8] Tang X, Deng Z, et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res. 2022 Mar 8.(11.161)南京中醫(yī)藥大學(xué)楊燁顧春艷團(tuán)隊(duì)

[9] Xie F, Su P, et al. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as  Therapy. Adv Mater. 2021 Oct 19. (IF:30.849)蘇州大學(xué)生物醫(yī)學(xué)研究院周芳芳團(tuán)隊(duì)和浙江大學(xué)生命科學(xué)研究院張龍團(tuán)隊(duì)

[10] Liang Y, Lu Q, et al. Reactivation of tumour suppressor in breast cancer by enhancer switching through NamiRNA network. Nucleic Acids Res. 2021 Sep 7.(IF:16.9)復(fù)旦大學(xué)生物醫(yī)學(xué)研究院于文強(qiáng)團(tuán)隊(duì)

[11] Fan Y, Wang J, et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021 Feb 2.(IF:27.403)南京醫(yī)科大學(xué)附屬逸夫醫(yī)院蘇東明團(tuán)隊(duì)

[12] Dai L, Dai Y, et al. Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin. Mol Cell. 2021 Jul 1.(IF:17.97)浙江大學(xué)生命科學(xué)研究院黃俊團(tuán)隊(duì)和中科院生物物理所周政團(tuán)隊(duì)

[13] Zhang K, Wang A, et al. UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model. Neuron. 2021 Jun 16.(IF:17.17)中國(guó)科學(xué)院生物與化學(xué)交叉研究中心王文元團(tuán)隊(duì)

[14] Li T, Chen X, et al. A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice. Nat Commun. 2021 Jan 27.(IF:14.92)華東理工大學(xué)生物工程學(xué)院楊弋團(tuán)隊(duì)

[15] Pan Y, He X, et al. Neuronal activity recruits the CRTC1/CREB axis to drive transcription-dependent autophagy for maintaining late-phase LTD. Cell Rep. 2021 Jul 20.(IF:9.420)浙江大學(xué)腦科學(xué)與腦醫(yī)學(xué)學(xué)院馬歡團(tuán)隊(duì)

[16] Liu H, Xing R, et al. G-protein-coupled receptor GPR17 inhibits glioma development by increasing polycomb repressive complex 1-mediated ROS production. Cell Death Dis. 2021 Jun 12.(IF:8.463)廈門大學(xué)生命科學(xué)學(xué)院陳穎團(tuán)隊(duì)

[17] Yan F, Huang C, et al. Threonine ADP-Ribosylation of Ubiquitin by a Bacterial Effector Family Blocks Host Ubiquitination. Mol Cell. 2020 May 21.(IF:17.97)浙江大學(xué)生命科學(xué)研究院朱永群團(tuán)隊(duì)

[18] Luo Q, Wu X, et al. TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. Cell Rep. 2020 Jan 7.(IF:9.42)中國(guó)醫(yī)學(xué)科學(xué)院分子腫瘤學(xué)國(guó)家重點(diǎn)實(shí)驗(yàn)室劉芝華團(tuán)隊(duì)

[19] Sun X, Peng X, et al. ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling. Nat Commun. 2020 Jun 12.(IF:14.911)中國(guó)科學(xué)院水生生物研究所孫玉華團(tuán)隊(duì)

[20] Yang X, Wang H, et al. Rewiring ERBB3 and ERK signaling confers resistance to FGFR1 inhibition in gastrointestinal cancer harbored an ERBB3-E928G mutation. Protein Cell. 2020 Dec.(IF:14.872)浙江大學(xué)醫(yī)學(xué)院/轉(zhuǎn)化醫(yī)學(xué)研究院閔軍霞團(tuán)隊(duì)

[21] Zou Y, Wang A, et al. Analysis of redox landscapes and dynamics in living cells and in vivo using genetically encoded fluorescent sensors. Nat Protoc. 2018 Oct.(IF:13.490)華東理工大學(xué)生物工程學(xué)院楊弋、趙玉政團(tuán)隊(duì)

[22] Hao H, Hu S, et al. Loss of Endothelial CXCR7 Impairs Vascular Homeostasis and Cardiac Remodeling After Myocardial Infarction: Implications for Cardiovascular Drug Discovery. Circulation. 2017 Mar 28.(IF:29.69)中國(guó)醫(yī)學(xué)科學(xué)院/北京協(xié)和醫(yī)學(xué)院阜外醫(yī)院王淼團(tuán)隊(duì)